George Clinical and EPS International Holdings Co., Ltd. announced that they have reached an agreement on a strategic partnership that will enhance their combined service offerings in Asia-Pacific, the world's most populous region, as well as worldwide for their respective clients.

Dr. Hisashi Tanaka, Representative Director and CEO of EPS International said, "EPSI aims to become the best partner for global expansion of pharmaceutical or medical device development focused on Asia-Pacific. I am so excited with this strategic partnership between George Clinical and EPSI since it enables EPSI to provide our clients with further value-added services.  We will create more robust capabilities when it comes to quality service provision in Asia-Pacific countries as we leverage George Clinical's excellent scientific leadership and extensive global investigator networks."

Glenn Kerkhof, Executive Chairman of George Clinical said, "The partnership with EPSI enables George Clinical to manage high quality clinical trials across the entire Asia-Pacificregion, including Japan, the third largest pharmaceutical market in the world. George Clinical was one of the first organizations to truly embrace the opportunities of conducting clinical trials across the Asia-Pacific region. As the region has developed into a sophisticated and desirable clinical trial location, so too has George Clinical developed into a highly-adaptable and scientifically led CRO, both regionally and globally. With the addition of EPSI's leading service provision in Japan, we will further enhance our customer experience while pursuing our strategic growth objectives to be a leading CRO partner in the region, providing global capabilities, and extending our ability to deliver early and late phase operational expertise deeper into Asia-Pacific."

The strategic partnership will see EPSI deliver clinical trial services for George Clinical clients in Japan. George Clinical will provide clinical trial services for EPSI and its Japanese customers across Asia, the United States and Europe.

In Asia, both companies will come together to provide a seamless operating capability for clinical trials across the Asia-Pacific region with the exception of China where both EPSI and George Clinical will maintain an independent operating presence.